Sunesis Pharmaceuticals, Inc. (SNSS) Launches Phase 3 VALOR Trial for Vosaroxin Drug
Today, Sunesis Pharmaceuticals, Inc. released updates on its pivotal Phase 3 VALOR trial of vosaroxin, the company’s lead drug candidate in the study of acute myeloid leukemia (AML). Sunesis announced that the first patient has been randomized and dosed with blinded study treatment. The VALOR trial is a multinational, randomized, double-blind, placebo-controlled, pivotal trial which is expected to enroll 450 evaluable patients at leading sites in the U.S., Canada, Europe, Australia and New Zealand. Patients in the VALOR trial will be randomized in blinded manner to receive either vosaroxin or placebo on days one and four of each treatment cycle.…